Molecular Partners Secures CHF93.1 Million Cash Runway While MP0712 Trial Kicks Off
Molecular Partners has launched a US Phase 1/2a trial of DLL3-targeting 212Pb Radio-DARPin MP0712 for SCLC and neuroendocrine cancers with initial clinical data due in 2026, while second Radio-DARPin MP0726 advances to first-in-human imaging. The company holds CHF93.1 million in cash and short-term deposits, securing runway through 2028.
1. Pipeline Progress
Molecular Partners initiated its US Phase 1/2a study of MP0712, a DLL3-targeting 212Pb Radio-DARPin candidate for small cell lung and other neuroendocrine cancers, with patient recruitment open and initial data expected in 2026. The second Radio-DARPin program, MP0726 targeting mesothelin, is progressing toward first-in-human imaging studies with candidate nominations anticipated by mid-2026, while investigator-initiated trials of CD40 agonist MP0317 in cholangiocarcinoma and multi-specific T cell engager MP0533 in AML continue dosing and development path updates.
2. Strategic Partnerships
The company co-develops Radio-DARPins MP0712 and MP0726 with Orano Med to leverage targeted alpha therapy expertise and entered a non-exclusive development agreement with Eckert & Ziegler to expand isotope options including 212Pb and 225Ac. A newly formed scientific advisory board, chaired by Prof. Ken Herrmann, will guide strategic development of targeted radiotherapeutics and accelerate transition from early validation to full clinical development.
3. Financial Position
As of December 31, 2025, Molecular Partners reported CHF93.1 million in cash and short-term deposits, providing an operational runway through 2028. This strong liquidity position underpins ongoing clinical programs and supports planned preclinical and imaging studies across its Radio-DARPin pipeline.